Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Cash & Equivalents (2023 - 2025)

Upstream Bio (UPB) has 3 years of Cash & Equivalents data on record, last reported at $72.2 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 119.02% year-over-year to $72.2 million; the TTM value through Sep 2025 reached $72.2 million, up 119.02%, while the annual FY2024 figure was $325.9 million, 1161.53% up from the prior year.
  • Cash & Equivalents reached $72.2 million in Q3 2025 per UPB's latest filing, up from $45.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $325.9 million in Q4 2024 and bottomed at $25.8 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $77.8 million, with a median of $47.3 million recorded in 2023.
  • The widest YoY moves for Cash & Equivalents: up 1161.53% in 2024, down 30.37% in 2024.
  • A 3-year view of Cash & Equivalents shows it stood at $25.8 million in 2023, then skyrocketed by 1161.53% to $325.9 million in 2024, then tumbled by 77.86% to $72.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $72.2 million in Q3 2025, $45.5 million in Q2 2025, and $71.3 million in Q1 2025.